Breaking News, Financial News

Financial Report: Covance 3Q

Late-Stage revenues up 19% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance 3Q Revenues: $606.7 million (+11%) 3Q Earnings: $44.2 million (+17%) YTD Revenues: $1.8 billion (+10%) YTD Earnings: $133.4 million (+119%) Comments: Late-Stage Development revenue grew 19% to $386 million in the quarter, driven by kit volumes and central lab services, up 26%, and clinical development revenue up 14%. Early Development revenue was $220 million, up 1%, with growth in clinical pharmacology, offset by declines in discovery support services and pharmaceutical chemistry s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters